Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection

Leukemia. 2020 Nov;34(11):3055-3059. doi: 10.1038/s41375-020-0913-y. Epub 2020 Jun 12.

Chunmei Yang^#^{1

2}, Mixue Xie^#^{1

2}, Kaifeng Zhang², Hui Liu³, Aibin Liang⁴, Ken H Young⁵, Wenbin Qian^{6

7}

¹ Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, Zhejiang, China.
² Institute of Hematology, Zhejiang University, Hangzhou, 310003, Zhejiang, China.
³ Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310009, Zhejiang, China.
⁴ Department of Hematology, Tongji Hospital of Tongji University, Shanghai, 200065, China. [email protected].
⁵ Hematopathology Division and Department of Pathology, Duke University School of Medicine, Duke University Medical Center and Cancer Institute, Durham, NC, 27710, USA. [email protected].
⁶ Institute of Hematology, Zhejiang University, Hangzhou, 310003, Zhejiang, China. [email protected].
⁷ Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310009, Zhejiang, China. [email protected].

^# Contributed equally.

No abstract available

Publication types